{
    "id": 10004,
    "fullName": "MCL1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MCL1 dec exp indicates decreased expression of the Mcl1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4170,
        "geneSymbol": "MCL1",
        "terms": [
            "MCL1",
            "bcl2-L-3",
            "BCL2L3",
            "EAT",
            "Mcl-1",
            "MCL1-ES",
            "mcl1/EAT",
            "MCL1L",
            "MCL1S",
            "TM"
        ]
    },
    "variant": "dec exp",
    "createDate": "08/04/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8235,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Mcl1 expression via shRNA resensitized Venclexta (venetoclax)-resistant acute myeloid leukemia cells to Venclexta (venetoclax) in culture (PMID: 27103402).",
            "molecularProfile": {
                "id": 10007,
                "profileName": "MCL1 dec exp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6583,
                    "pubMedId": 27103402,
                    "title": "Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2682,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, knockdown of Mcl1 in cancer cell lines increased sensitivity to ABT-737 in culture (PMID: 22898329).",
            "molecularProfile": {
                "id": 10007,
                "profileName": "MCL1 dec exp"
            },
            "therapy": {
                "id": 1772,
                "therapyName": "ABT-737",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3384,
                    "pubMedId": 22898329,
                    "title": "Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22898329"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10098,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MCL1 knockdown sensitized PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663).",
            "molecularProfile": {
                "id": 27251,
                "profileName": "MCL1 dec exp PIK3CA wild-type"
            },
            "therapy": {
                "id": 5373,
                "therapyName": "WEHI-539",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8002,
                    "pubMedId": 27974663,
                    "title": "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27974663"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10007,
            "profileName": "MCL1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27251,
            "profileName": "MCL1 dec exp PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}